Innovative Transdermal Technologies

Table of Contents

1Com

pany

Hist

ory &

Org

aniza

tion

3AVERSA

4Pub

lic P

rofile

NTRB

Subsid

iaries

and

Cap

abilit

ies

2

2

Company History & OrganizationCreating Products to meet the needs of

Physicians, Patients and Payers (the 4 P’s)

1

Company Timeline

2012Nutriband Ltd. Founded inDublin, Ireland

Research conducted on Transdermal technologies in healthcare and pharmaceutical space. Business plan developed.

2012-2015

2016Nutriband Inc.established in Orlando,FL. Acquires NutribandLtd. (Ireland)

2018

2020Nutriband Inc.’s Abuse Deterrent Patent filed by its subsidiary 4P Therapeutics not granted and issued in Europe, UK, Japan, Korea, Australia, Russia, Mexico with prosecution continuing in US, Canada and China.

Nutriband Inc. Acquires 4P Therapeutics for $1.9MM paid in Company Stock and Cash. 4P Therapeutics Abuse Deterrent technology becomes the Lead product in Nutriband Inc.’s pipeline

2016Nutriband Inc. files Form10 with SEC, lists on OTCmarket.

2020

December – Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Hospital Group for its Closed System Transfer Device

2020Nutriband Inc. acquires Pocono Coated Products Topical Transdermal manufacturing Division and Active Intelligence LLC for $7.5MM in Company Stock and Cash. Pocono Pharmaceuticals established as a subsidiary.

2021

Organizational Chart

CEO: Gareth SheridanCore Objective: Develop a transdermal abuse deterrent technology for Fentanyl patches, called AVERSA. With FDA approval AVERSA will revolutionize the safety standard for opioid based medications and save countless lives per year. Follow on projects include transdermal delivery of peptides and proteins targeting the Diabetes market

Core Objective: 4P Therapeutics is a clinical subsidiary of Nutriband Inc. (NTRB) focused on the research and development of novel drug delivery technologies and therapeutics. 4P develops products that meet the needs of patients, physicians and payers.

Core Objective: Leverage our existing transdermal technology to bring new & innovative products to the market.

Division Head: Dr. Alan Smith

Division Head: Tyler Overk

Division Head: Michael Myer

Core Objective: Ensure the delivery of tailored topical/transdermal products and solutions designed to meet our partners needs.

Capabilities● Contract Manufacturing

(Pocono)

● Testing and Release (Pocono)

● Quality Systems (Pocono / 4P)

● R&D / Clinical Development

● Nutriband Core Pipeline

2

460,000,000+

9

Topical / Transdermal Patches Manufactured to Date

Average annual growth rate of 60% (2018-2021)

Manufacturing

1MM Patches1.25”x1.25” patch

10

Over 250,000 Kinesiology Tape Strips 2”x10” (12,500 rolls w/20 strips)

Larger patch daily output is over 450,000 (3”x5”)

Daily Coating Capacity

Research & Development4P Therapeutics:The company has capabilities for developingpharmaceutical products from pre-clinical testingto clinical manufacturing and early stage clinicaldevelopment (Phase I/II). A key company focus andarea of expertise is in the development oftransdermal products for currently injectedcompounds, including proteins, peptides,macromolecules and biologics. Transdermaldelivery of commercially available drugs or biologicsthat are typically delivered via injection has thepotential to improve safety, efficacy andtherapeutic outcomes associated with thesetreatments

Core Prescription Pipeline

Exenatide● Dermal ablation

technology to deliver peptides.

● Indication for type 2Diabetes.

AVERSA®:● Abuse Deterrent

technology for opioid based medications

● Chonic Pain● TDS Delivery● Model to be proven

with Fentanyl market.● Applications range to all

potentially harmful orabusable Trandsdermaland topical medications.

FSH● Dermal ablation technology

applied to FSH for injection free delivery.

● Indication for Fertilitytreatment

AVERSA overview3

Public Profile NTRB

4

Stock symbol: NTRBTrading Market: OTCQB

As of Feb 8, 2021

Partners and Customers Served

16

NTRB Locations

Transdermal Patches/ partners / customers